Videos

Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.

Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.

In this closing segment, the panel reflects on ongoing unmet needs in the first line management of EGFR mutated metastatic non-small cell lung cancer.

In this segment, the discussion returns to the theme of long term management in EGFR mutated metastatic non-small cell lung cancer.

According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

Diane Simeone, MD, discussed results from the RASolute 302 trial, which showed improved overall survival with daraxonrasib vs SOC in metastatic PDAC.

The final portion of the program shifts to case-based discussion, with the panel applying earlier debates to real-world clinical scenarios in relapsed/refractory DLBCL. The first case, a fit 58-year-old with early relapse, prompts consensus around rapid movement to CAR-T therapy with bridging strategies such as polatuzumab-based regimens, whereas the second case highlights challenges related to primary refractory disease and inconsistent caregiver support. The program concludes with closing remarks and a debate winner announcement, reinforcing the collaborative nature of evolving treatment strategies in LBCL.

Early trials exploring the efficacy of PD-1 blockade in Hodgkin lymphoma inspired the SWOG S1826 trial, which evaluated the agent with AVD in this population.

Surgical approach and adherence to endocrine therapy were predictors of locoregional recurrence in women diagnosed with breast cancer at age 40 or younger.

Minimal residual disease negativity may negate the need to wait 5 to 10 years for updated findings to inform treatment decision-making in multiple myeloma.

Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a clinical scenario of a patient with disease progression after frontline dual immune checkpoint inhibitor therapy, emphasizing the need to individualize second-line treatment decisions in the absence of certain emerging approvals.

In this segment on advanced renal cell carcinoma, Dr. Ornstein explores real-world transition rates from first-line to subsequent lines of therapy, asking how often patients reach second- and third-line treatment in clinical practice.

Iberdomide and mezigdomide have achieved positive phase 3 results in multiple myeloma, according to Shebli Atrash, MD.

Elizabeth Mittendorf, MD, discussed how the Clarity Breast AI algorithm can complement tools such as the Tyrer-Cuzick model to define breast cancer risks.

In this segment, Dr. Devarakonda asks Dr. Rotow to address the role of dose interruptions and reductions in managing treatment related toxicities in EGFR mutated metastatic non-small cell lung cancer.

In this segment, the discussion shifts to a 70 year old patient with EGFR mutated metastatic non-small cell lung cancer who is experiencing dermatologic toxicity several months into first line EGFR targeted therapy.

Constant adjustments during high-intensity focused ultrasound may help minimize damage to healthy tissue in prostate cancer treatment.

Sarah Weiss, MD, discussed key IGNYTE trial findings of RP1 and nivolumab in patients with advanced melanoma who progressed on prior anti-PD-1 therapy.

The teams debate whether CAR-T or bispecific antibodies should be prioritized as the treatment paradigm evolves in relapsed large B-cell lymphoma, with Team NYC centering the argument on “cure” and the curative-intent potential/plateau of CAR-T outcomes. Team Roswell agrees cure is the goal but argues that real-world access barriers and “off-the-shelf” availability make bispecifics, and especially emerging combination strategies, crucial for patients who cannot reliably reach or complete CAR-T. The discussion highlights a key tradeoff: CAR T as a one-time, time-limited intervention vs bispecifics requiring ongoing dosing and infrastructure, with durability, infection risk, and sequencing still actively evolving.

Roisin E. O’Cearbhaill, MD, discussed the MUC16 × CD28 bispecific antibody REGN5668 in treating patients with recurrent ovarian or endometrial cancer.

Elizabeth Mittendorf, MD, PhD, discusses Clarity Breast, an FDA-authorized AI tool that predicts 5-year breast cancer risk using standard 2D mammograms.